9PL.F GENINCODE PLC LS -01

Healthcare Biotechnology Frankfurt Exchange
0.0055 EUR
Close of Nov 11, 2026
0.0005 0.0825
Market cap
EUR 4.14M
P/E
-
P/B
1.68x
ROE
-4,600.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 9PL.F undervalued?

Graham number

The Graham number of GENINCODE PLC LS -01 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

GENINCODE PLC LS -01 fundamental analysis

No fundamental analysis for GENINCODE PLC LS -01 yet.

GENINCODE PLC LS -01 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About GENINCODE PLC LS -01

GENinCode Plc engages in the development and commercialization of clinical genetic tests for predictive analysis of risk to a patient's health based on genes in the United Kingdom, Spain, Italy, the United States, Germany, and internationally. The company offers CARDIO inCode Score, a genetic test to evaluate the risk of coronary heart disease; LIPID inCode, a genetic test for the diagnosis of familial hypercholesterolemia with further coronary risk stratification of the pat…

Full company profile